CDT Equity Inc.
CDTTW
NASDAQ Capital Market0.02
USD
+0.01
- -
CDT Equity Inc.
CDTTW
(NASDAQ Capital Market)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CDT Equity Inc. (NASDAQ: CDT, CDTTW) is a clinical-stage biopharmaceutical company that identifies, enhances and advances high-potential therapeutic assets through artificial intelligence, solid-form chemistry and strategic partnerships; its pipeline targets autoimmune disorders including uveitis and Hashimoto's thyroiditis, idiopathic male infertility, oncology, dermatology and animal health with candidates such as AZD1656, a glucokinase activator that has completed Phase I trials, and AZD5904; the company employs co-crystallization technologies at its Cambridge, UK facilities to improve drug properties and extend patent life by up to 20 years, alongside AI-driven disease mapping for repurposing deprioritized clinical compounds. Founded in 2019 and headquartered in Naples, Florida, CDT Equity operates a lean, disease-agnostic model focused on in vitro and in vivo studies to support licensing deals and commercialization partnerships with third parties, while serving human and animal health markets through efficient asset repositioning. Originally established as Conduit Pharmaceuticals Inc., the company rebranded as CDT Equity in 2024 to reflect its expanded platform; recent developments include strategic partnerships with Sarborg for AI disease mapping, Manoira for animal health insights, and Agility Life Sciences for solid oral-dosage formulations, alongside a cryptocurrency treasury strategy featuring acquisitions of approximately 17.9 bitcoin as of October 2025, a 1-for-8 reverse stock split effective October 2025 and identification of new biological targets validating its AI repurposing approach.